Compare Cytokinetics Inc (CYTK) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Veritone Inc — how do they compare? Cytokinetics Inc trades at $77.39 (market cap $10.63B), while Veritone Inc trades at $1.51 (market cap $138.04M). The key difference: Cytokinetics Inc is far larger — about 77× Veritone Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | VERI | |
|---|---|---|
Market Cap | $10.63B | $138.04M |
Sector | Technology | Technology |
52-Week High | $87.26 | $8.39 |
52-Week Low | $34.31 | $1.00 |
Enterprise Value | $10.74B | $170.07M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Veritone (VERI) trades at $1.31, up 4.8% today, with a bullish technical signal despite negative profitability metrics. The company reported Q1 2026 revenue of $90M but missed earnings expectations with a net loss of $111M. Recent business developments include AI partnership expansions with government agencies and new redaction capabilities, while facing multiple securities class action lawsuits alleging improper revenue accounting.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus shows divided sentiment with 46% buy ratings. Key risks include ongoing litigation, execution challenges in achieving profitability, and competitive pressures in the enterprise AI sector. The stock's low price presents speculative potential but requires careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
